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تقومي فعالية تدخل الصيدالين السريري حلل املشاكل السريرية والدوائية عند 
املرضى الداخليني املصابني مبرض القلب التاجي
دراسة استباقية قبل-جتريبية يف مستشفى عام بإندونيسيا
فينا اأنا�ستازيا �ساجتا، اأنتون بهتيار، ريتنو�ساري اندراجاتي
abstract: Objectives: This study aimed to evaluate the role of a clinical pharmacist intervention in decreasing 
subsequent clinical and drug-related problems (DRPs) among coronary heart disease (CHD) inpatients with at least 
one previous DRP. Methods: This pre-experimental study with a pre-post design was carried out from January to April 
2017 among inpatients with at least one previous DRP at a general hospital in Tangerang District, Banten, Indonesia. 
Clinical and DRPs were documented prospectively by a clinical pharmacist, with DRPs classified using Version 
6.2 of the DRP classification scheme of the Pharmaceutical Care Network Europe Foundation. The intervention 
consisted of a discussion of identified DRPs with physicians, patients, pharmaceutical logistics clerks, nurses and 
nutritionists. Following this, any subsequent clinical and DRPs were re-identified and further interventions were 
conducted as necessary. Results: A total of 75 inpatients were included in the study. Pre-intervention, there were 
443 DRPs and 202 clinical problems. The most frequent DRPs were adverse drug reactions (52.6%), followed by 
drug effects (41.8%). Most DRPs were of moderate severity and would have resulted in moderate consequences had 
the pharmacist not intervened. The interventions resulted in a significant reduction in the number of DRPs, type of 
DRPs and number of clinical problems (P <0.05 each). Patients with complications were 26.047 times more likely 
to have no reduction or an increased number of clinical problems compared to patients without complications 
(P <0.05). Conclusion: Clinical pharmacist interventions were found to reduce subsequent DRPs and clinical 
problems among CHD patients with at least one previous DRP.
Keywords: Coronary Heart Disease; Drug Interactions; Adverse Drug Reactions; Pharmacists; Indonesia.
امللخ�ص: الهدف: تهدف هذه الدرا�سة لتقومي دور ال�سيدالين ال�رصيري يف التدخل لتقليل امل�ساكل ال�رصيرية والدوائية الالحقة عند املر�سى 
الداخليني امل�سابني مبر�ض القلب التاجي الذين تعر�سوا من قبل لنوبة واحدة من ذلك املر�ض، على االأقل. الطريقة: اأجريت هذه الدرا�سة 
اال�ستباقية قبل-التجريبية يف الفرتة من يناير اإىل اأبريل من عام 2017م على مر�سى اأ�سيبوا من قبل بنوبة واحدة على االأقل بهذا املر�ض، 
وذلك يف م�ست�سفى عام يف منطقة تاجنارانق ببانتنج يف اإندوني�سيا. وقد �سجلت و�سنفت كل م�ساكل املر�سى ال�رصيرية والدوائية بوا�سطة 
�سيدالين �رصيري با�ستخدام الن�سخة رقم 6.2 من نظام ت�سنيف امل�ساكل الدوائية الذي اأ�سدرته �سبكة الرعاية ال�سيدالنية االأوروبية. و�سمل 
التدخل مناق�سة للم�ساكل املتعرف عليها مع االأطباء واملر�سى وكتبة اخلدمات اللوج�ستية ال�سيدالنية واملمر�سات واخت�سا�سي التغذية. 
وعقب ذلك مت التعرف على اأي م�ساكل �رصيرية اأو دوائية الحقة، ومت التدخل فيها عند ال�رصورة. النتائج: �سمت هذه الدرا�سة 75 مري�سا. 
 )52.6%( اأكرث امل�ساكل الدوائية حدوثا هي االآثار اجلانبية  202 م�سكلة �رصيرية. وكانت  443 م�سكلة دوائية و  وكان هنالك قبل التدخل 
وتلتها اآثار الدواء )%41.8(. وكانت معظم امل�ساكل الدوائية متو�سطة ال�سدة، وكان من املمكن اأن حتدث نتائج ذات اآثار متو�سطة ال�سدة لوال 
تدخل ال�سيديل ال�رصيري، اإذ اأف�سى ذلك التدخل خلف�ض معنوي يف اأعداد واأنواع امل�ساكل ال�رصيرية والدوائية عند املر�سى )P >0.05، يف 
احلالتني(. وكان احتمال زيادة امل�ساكل ال�رصيرية اأو عدم نق�سان عددها اأكرب مبقدار 26.047 مرة اأ عند املر�سي الذين تعر�سوا مل�ساعفات 
من الذين مل يتعر�سوا مل�ساعفات )P >0.05(. اخلال�صة: وجدنا اأن تدخل ال�سيديل ال�رصيري يقلل من امل�ساكل ال�رصيرية والدوائية الالحقة 
عند املر�سى الداخليني امل�سابني مبر�ض القلب التاجي الذين تعر�سوا من قبل لنوبة واحدة من املر�ض على االأقل.
الكلمات املفتاحية: مر�ض القلب التاجي؛ تفاعل االأدوية؛ االآثار ال�سارة لالأدوية؛ ال�سيادلة؛ اأند ون�سيا.
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Advances in Knowledge
- A clinical pharmacist intervention was found to significantly reduce clinical and drug-related problems (DRPs) among coronary heart 
disease (CHD) inpatients with at least one previous DRP at a general hospital in Indonesia. 
- The most frequent type of potential DRPs observed in the study were adverse drug reactions. Most DRPs were of moderate severity and, 
without intervention, were forecast to result in moderate consequences with regards to the health of the patients.
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Nearly one-third of all deaths world- wide are due to cardiovascular diseases (CVDs), with coronary heart disease (CHD) 
the leading cause of CVD-related deaths.1,2 In 2015, the 
World Health Organization estimated that approxi-
mately 17.7 million people died globally as a result of 
CHD.3 In Europe, CVD was responsible for four million 
deaths in 2015, with CHD the cause of 19% and 20% 
of deaths among men and women, respectively.4 A 
total of 15.5 million people in the USA were found to 
be living with CHD in 2016.5 In Indonesia, the overall 
prevalence of CHD in 2013 for individuals aged 15 
years and over was 0.5% based on an official diagnosis 
and 1.5% based on a diagnosis or related symptoms; 
this increased to 1.7% and 3.2%, respectively, in those 
over 75 years old.6 For those in the 15–24-year-old age 
group, the prevalence was 0.1% based on a diagnosis 
and 0.7% based on a diagnosis or symptoms.6
In CHD, the coronary arteries that supply oxygen 
to the heart become narrower due to a build-up of 
plaque. The disease may clinically manifest as stable 
angina (i.e. chest pain) or acute coronary syndrome 
(ACS).7 The goal of CHD treatment is to control these 
symptoms and prevent progression of the disease by 
reducing relevant risk factors such as hypertension and 
dyslipidaemia.8 It is common for patients to take five or 
more drugs simultaneously as part of lifelong therapy. 
Unfortunately, polypharmacy increases the risk of a 
drug-related problem (DRP), defined as an event or 
circumstance involving drug therapy that can interfere 
with a desired health outcome.9 
The occurrence of DRPs can reduce the benefits 
of drugs and cause increased morbidity and mortality.10 
According to the classification scheme of the Pharma-
ceutical Care Network Europe Foundation (PCNEF), 
four types of DRPs exist, including drug effects, adverse 
drug reactions (ADRs), treatment cost-related problems 
and other problems.11 Cases involving inappropriate 
drug dosages, regimens or drug interactions and poor 
adherence to a drug regimen may result in drug treat- 
ments having non-optimal effects or no effect. Other 
DRPs include non-allergic ADRs, unnecessary drug 
treatment and patient dissatisfaction with therapy.12 
The detection and prevention of DRPs can enhance 
the quality of life of patients and optimise healthcare 
costs.10 In 2004, a study from Norway found that 81% 
of hospitalised patients had DRPs.13 Other research has 
indicated that between 69–78% of CVD patients have 
DRPs.14,15 In 2011, a study reported that cardiovascular 
drugs were one of the major causes of all DRPs.16 
Identified risk factors for ADRs include age, gender, 
polypharmacy, drug administration with a narrow 
therapeutic index, decreased renal elimination and the 
use of oral anti-coagulants and diuretics.17
Pharmacists can help to identify and resolve DRPs 
through appropriate interventions.10 Examples of phar- 
macist interventions include advising patients of drug 
information and instructions for use or changing the 
drug prescription, dosage, formulation or regimen. In 
addition, if needed, pharmacists can also provide medi- 
cation counselling and education for patients regarding 
ADR presentations and drug interactions.12 Research 
has shown that involving pharmacists in multi-
disciplinary teams decreases morbidity and mortality.18 
A study performed in Indonesia evaluated the role of 
pharmacist interventions in decreasing DRPs among 
CVD and stroke inpatients.19 This study aimed to eval- 
uate the number and type of DRPs and clinical prob-
lems following a clinical pharmacist intervention among 
CHD inpatients with at least one previous DRP at a 
general hospital in Tangerang District, Banten, Indonesia. 
It was hypothesised that the intervention would result 
in a reduction in DRPs and an improvement in the 
inpatients’ clinical condition.
Methods
This pre-experimental prospective study with a pre-
post design was carried out from January to April 
2017 at a general hospital in Tangerang District. Only 
inpatients aged ≥35-years-old with national health 
insurance, who had been diagnosed with CHD, were 
receiving CHD medications and had experienced 
at least one DRP previously were included in the 
study. Patients with infectious diseases and pregnant 
or lactating women were excluded, as well as patients 
with incomplete medical records or those who were 
unwilling to participate or lost to follow-up during the 
study period. Out of 111 inpatients, 21 patients were 
unwilling to participate, three did not have a DRP and 
12 patients were diagnosed with infections, resulting 
in a total sample of 75 inpatients.
The drug therapy details, laboratory parameters 
and demographic details of all inpatients were pros-
pectively reviewed by a clinical pharmacist. During 
ward rounds, drug and dose selection, drug regimens 
and patients’ drug use patterns were evaluated in 
Application to Patient Care
- The findings of this study may be used by physicians, pharmacists and other healthcare workers in order to reduce DRPs and clinical 
problems among CHD inpatients.
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order to identify DRPs as per Version 6.2 of the 
PCNEF classification scheme.11 Interventions consis-
ted of reporting and discussing identified DRPs during 
interviews with various recipients, including physicians, 
patients, pharmaceutical logistics clerks, nurses and 
nutritionists. The type of intervention was classified as 
either independent (i.e. specifically tailored to an indiv-
idual recipient) or concurrent (i.e. provided to several 
or all recipients at the same time). It is important to 
note that each DRP could be targeted with more than one 
intervention. After the interventions, the pharmacist 
continued monitoring the patient until discharge, 
conducting further interventions as necessary for 
any subsequent DRPs. 
The overall number of clinical problems and the 
overall number and subtypes of DRPs before and after 
the intervention were calculated for every patient. 
A specific subtype of DRP could occur as a result of 
different drugs. The severity of identified DRPs was 
classified as major, moderate or minor.20 Major DRPs 
were defined as those requiring intervention to prevent 
major or irreversible detrimental effects or due to 
lack of appropriate therapy in circumstances where 
evidence-based options were available. Moderate DRPs 
included DRPs whereby interventions would result in 
moderate benefit for the patient, while minor DRPs 
were defined as those requiring only minor adjustments, 
such as modifications to dosage timings.20 Harmful, 
unpleasant and unintended responses to drugs at normal 
doses were considered to constitute ADRs.17
The probable consequences of a lack of interven-
tion were categorised as insignificant, minor, moderate, 
major or catastrophic.20 For example, insignificant con- 
sequences referred to circumstances where no harm 
or injury to the patient and a low financial loss would 
result as a lack of intervention. Minor consequences 
included minor injuries, minor treatment, no pro-
longed length of stay (LOS) or re-admission to the 
hospital and the potential for minor financial loss, 
while moderate consequences included major temporary 
injuries, prolonged LOS or re-admission to the hosp-
ital, a cancellation or delay in planned treatments/
procedures and the potential for financial loss. Major 
consequences included major permanent injuries, pro-
longed LOS or re-admission to the hospital, morbidity 
upon discharge and the potential for significant financial 
loss. Finally, catastrophic consequences of a lack of 
intervention included the death of the patient, the 
potential for large financial losses and/or threat to the 
patient’s goodwill or reputation.20
Data were analysed using the Statistical Pack-
age for the Social Sciences (SPSS), Version 23.0 (IBM 
Corp., Armonk, New York, USA). A Wilcoxon signed- 
rank test was used to assess the differences between 
pre- and post-intervention DRPs and clinical problems. 
A Chi-squared test was used to assess the relationship 
between DRPs and risk factors such as age, gender, 
clinical manifestations, LOS, comorbidities, complica-
tions from other CVDs and the number of drugs 
administered. Logistic regression was used for the multi- 
variate analysis of risk factors (advance test). A P value 
of <0.05 was considered statistically significant. 
Ethical approval for this study was obtained from 
the Ethics Committee of the Faculty of Medicine at the 
University of Indonesia (#956/UN2.F1/ETIK/2016). 
Informed consent was provided by all patients and/or 
Table 1: Demographic and clinical characteristics of 




















Number of drugs prescribed
1–5 19 (25.3)
>5 56 (74.7)
ACS = acute coronary syndrome; LOS = length of stay.
Table 2: Acceptance of a clinical pharmacist intervention 
for clinical and drug-related problems among coronary 
heart disease inpatients in Indonesia (N = 459)
Acceptance of intervention n (%)
No intervention 2 (0.4)
Not accepted 14 (3.1)
Accepted 443 (96.5)
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their relatives. Data confidentiality and security were 
ensured throughout the study period.
Results
The mean age of the patients was 56.4 ± 8.4 years, with 
the majority being 35–59 years old (64%). Most of the 
patients were male (70.7%). The most frequent clinical 
manifestations of CHD among the patients were non-
ACS symptoms (66.7%) [Table 1]. The median LOS 
was two days (interquartile range [IQR]: 2–4 days), 
with 92% staying 1–5 days. The median number of 
comorbidities was two (IQR: 1–3). Hypertension 
(96%), cholesterol (38.7%) and type 2 diabetes mellitus 
(30.7%) were the most common comorbidities. The 
majority of the patients had no complications (80%). 
Overall, a total of 561 different kinds of drugs were 
prescribed, falling into 44 drug classes. The most 
common class was antihypertensives (33.6%), followed 
by antiplatelets (21.6%) and anticholesterol medications 
(12.8%). Patients received a median of seven different 
types of drugs (IQR: 5–9 types).
The pharmacist interventions were not fully 
accepted (96.5%) [Table 2]. Initially, a total of 443 
DRPs and 202 clinical problems were identified and 
received interventions. Patients had a median of five 
DRPs (IQR: 4–8 DRPs). There were 199 different 
subtypes of DRPs, with patients experiencing a median 
of three subtypes (IQR: 2–3 subtypes) [Table 3]. 
Nonoptimal drug effects (37.5%), non-allergic ADRs 
(39.1%) and unnecessary drug treatments (1.8%) were 
the dominant subtypes of DRPs [Table 4]. Post-percut-
aneous coronary intervention hand pain (27.2%), chest 
pain (21.8%) and shortness of breath (11.4%) were the 
dominant pre-intervention clinical problems [Table 5]. 
Pre-intervention DRPs varied in terms of severity, 
with 35 minor (7.9%), 336 moderate (75.8%) and 72 
major (16.3%) DRPs. Interventions were performed 
for 138 actual (31.2%) and 305 potential (68.8%) DRPs. 
Of the actual DRPs, 107 (77.5%) were attributable to 
drug effects, 22 (15.9%) were attributable to ADRs and 
nine (6.5%) were due to treatment cost-related problems. 
For the potential DRPs, 77 (25.2%) and 228 (74.8%) 
were due to drug effects and ADRs, respectively 
[Table 6]. The most predominant type of intervention for 
DRPs was concurrent (n = 310; 70%). The consequences 
of a lack of intervention for DRPs were projected to 
be insignificant in two cases (0.5%), minor in 33 cases 
(7.4%), moderate in 336 cases (75.8%), major in 71 
cases (16%) and catastrophic in one case (0.2%).
Following the intervention, there were 53 DRPs, 
37 subtypes of DRPs and 26 clinical problems [Table 3]. 
Table 3: Drug-related and clinical problems before and after a clinical pharmacist intervention among coronary heart 
disease inpatients in Indonesia (N = 75)
Pre-intervention Post-intervention P 
value*
n Mean ± SD Median (IQR) n Mean ± SD Median (IQR)
Clinical problems 202 2.69 ± 0.97 2 (2–4) 26 0.35 ± 0.73 0 (0) <0.01
Number of DRPs 443 5.91 ± 3.22 5 (4–8) 53 0.71 ± 1.30 0 (0–1) <0.01
Types of DRPs 199 2.65 ± 0.78 3 (2–3) 37 0.49 ± 0.66 0 (0–1) <0.01
SD = standard deviation; IQR = interquartile range; DRP = drug-related problem.
*Using a Wilcoxon signed-rank test.
Table 4: Number and subtype of drug-related problems 
before and after a clinical pharmacist intervention among 






Drug effects 184 (41.5) 28 (6.3)
None 0 (0) 0 (0)
Nonoptimal 166 (37.5) 22 (4.5)
Wrong effect 0 (0) 0 (0)
Indication 
untreated 
18 (4.1) 8 (1.8)
ADRs 250 (55.8) 25 (5.6)
Non-allergic 173 (39.1) 22 (5)
Allergic 0 (0) 0 (0)
Toxic 77 (17.4) 3 (0.7)
Treatment cost-
related
9 (2) 0 (0)
More costly than 
necessary 
1 (0.2) 0 (0)
Unnecessary 
treatment
8 (1.8) 0 (0)
Other 0 (0) 0 (0)
Patient 
dissatisfaction†
0 (0) 0 (0)
Unclear‡ 0 (0) 0 (0)
DRP = drug-related problem; ADR = adverse drug reaction.
*Post-intervention percentages are calculated out of the total number of 
pre-intervention DRPs. There was an 88% reduction in the overall number 
of DRPs following the intervention.  †Despite optimal clinical and economic 
treatment outcomes.  ‡More clarification necessary.
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Overall, the number and subtypes of DRPs significantly 
decreased by 88% and 81.4%, respectively, while clinical 
problems significantly decreased by 87.1% (P <0.01 each). 
Clinical manifestations of CHD were associated with 
a reduction in clinical problems, although this differ-
ence was not statistically significant (P = 0.21). In 
addition, the effect of age and comorbidity on the 
number of DRPs was also not significant (P = 0.18 
and 0.16, respectively). While clinical problems were 
significantly affected by age (P = 0.02), the effect of 
comorbidities was not significant (P = 0.21). Con-
versely, there was a significant reduction in the num-
ber of DRPs, subtypes of DRPs and clinical problems 
among patients with complications (P = 0.04 each). 
In the advance test, patients with complications were 
26.047 times more likely to have an increase or no 
reduction in the number of clinical problems comp-
ared to patients without complications (P <0.05). 
Discussion
Advanced age is a major risk factor of myocardial 
infarction, a cause of ACS-related CHD.21,22 According 
to previous research, the majority of CHD patients 
in Indonesia are elderly (>75 years old).6 However, 
most of the patients in the current study were middle-
aged; this is likely due to the high proportion of non- 
ACS-related CHD cases. According to the American 
Heart Association, nearly half of all males and one-
third of all females between 40–60 years old in the 
USA will develop some manifestation of CHD.5 This 
finding is in agreement with the results of the current 
study. Moreover, the majority of the patients in the 
current study did not have complications; once again, 
this may be because most were not elderly and 
therefore still had well-functioning organs. The LOS 
varied from 1–5 days for the majority of patients. 
This is in accordance with the unpublished clinical 
protocols of the studied hospital, which recommends a 
treatment plan of five days.
In the current study, patients received a median 
of seven drugs. A previous study reported a range 
of 6–16 cardiovascular drugs prescribed to patients 
in India.10 Antihypertensives, antiplatelets and anti-
cholesterol medications are the primary treatments 
for CHD.23 Accordingly, these drugs were the most 
frequently prescribed classes of drugs in the present 
study. However, while the majority of patients in the 
current study did not have ACS-related symptoms or 
complications, it was noted upon review that more ACS 
drugs were prescribed than non-ACS drugs.23 In terms 
of severity, most of the DRPs in the present study 
were moderate; similarly, Shareef et al. noted that 
58.5% of DRPs among CHD patients in a hospital in 
Table 5: Number of clinical problems before and after a clin-
ical pharmacist intervention among coronary heart disease 
inpatients in Indonesia (N = 202)







Chest and hand pain 6 (3) 0 (0)
Chest pain and a burning 
sensation
3 (1.5) 0 (0)
Chest pain and a sensation of 
heaviness
4 (2) 0 (0)
Chest, back and shoulder pain 21 (10.4) 0 (0)
Chest pain 44 (21.8) 1 (0.5)
Palpitations 4 (2) 1 (0.5)
Epigastric pain 5 (2.5) 0 (0)
Nausea 10 (5) 1 (0.5)
Vomiting 2 (1) 0 (0)
Cold sweat 7 (3.5) 0 (0)
Coughing 4 (2) 3 (1.5)
Shortness of breath 23 (11.4) 6 (3)
Headache/vertigo 4 (2) 1 (0.5)
Post-PCI/CA hand pain 55 (27.2) 1 (0.5)
Swallowing pain 1 (0.5) 0 (0)
Joint pain - 2 (1)
Diarrhoea 1 (0.5) -
Constipation 1 (0.5) 0 (0)
Melaena 1 (0.5) 0 (0)
Easily fatigued 4 (2) 5 (2.5)
Haematuria 1 (0.5) 0 (0)
Back and shoulder pain - 2 (1)
Restless sleep 1 (0.5) 1 (0.5)
Oedema - 2 (1)
PCI = percutaneous coronary intervention; CA = coronary angiography.
*Post-intervention percentages are calculated out of the total number of pre-
intervention clinical problems. There was an 87.1% reduction in the overall 
number of DRPs following the intervention.
Table 6: Pre-intervention drug-related problems among 




























DRP= drug-related problem; ADR = adverse drug reaction.
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India were moderately severe.24 The most common 
type of DRPs in the present study were potential 
ADRs. These likely occurred because the recomm-
ended drug therapies for CHD patients are anti-
anginal, fibrinolytic and anticoagulant medications, 
which can have many drug interactions and therefore 
result in a higher risk of ADRs.23,25 In contrast, drug 
effects caused the greatest number of actual DRPs; 
such problems may be due to the inappropriate timing 
and/or dosing intervals of drugs or failure on the 
part of the patient to take the drugs as prescribed.
Most interventions for DRPs in the present study 
were given concurrently to multiple recipients in order 
to increase awareness of potential drug interactions. 
In order to properly manage potential DRPs caused by 
drug interactions, separate and specifically timed doses 
of different drugs are recommended.23,25 Although 
clinicians in the current study seemed aware of these 
recommendations, the task of administering medica-
tions fell primarily to nurses who may not have been 
as equally well-informed. In addition, there was often 
not enough time to re-check correct drug dosages and 
certain dietary instructions regarding potential food-
drug interactions were not properly communicated to 
nutritionists. Such logistical shortcomings should be 
addressed. The consequences of a lack of pharmacist 
intervention for most DRPs in the present study were 
deemed to be moderate as it was assumed that no in- 
tervention would have risked the health of the 
inpatients.
Gattis et al. found that the inclusion of a 
pharmacist on multidisciplinary teams significantly 
reduced mortality and heart failure events among 
patients with CVDs.18 The results of the current study 
similarly underline the importance of pharmacists, 
in that the intervention significantly decreased the 
number and type of DRPs and the number of clinical 
problems among CHD inpatients. This was in line 
with a comparable study of CVD patients in India, 
which demonstrated that a clinical pharmacist inter- 
vention positively influenced cardiovascular health-
care management by preventing and resolving DRPs.24 
Another study in Indonesia also observed that a pharm-
acist intervention significantly decreased DRPs among 
stroke and CVD patients in an intensive care unit.19
In the current study, only age significantly affected 
the number of clinical problems post-intervention, 
while complications affected the number and subtypes 
of DRP and number of clinical problems. Since the 
type of CHD can influence the drug treatment 
required, it may also have affected the number of DRPs.23 
Age-related physiological changes can also affect the 
pharmacokinetic and pharmacodynamic properties of 
medication.26 In the current study, the presence of 
complications was found to significantly increase the 
chance of an increase or no reduction in clinical 
problems by 26.047 compared to patients without 
complications. Cardiovascular complications causing 
heart remodelling or aortic stenosis could result in a 
deterioration of the patient’s clinical condition.25 
This study was subject to certain limitations. 
The identification and evaluation of DRPs and the 
content of the interventions were based solely on 
information from the available literature and the 
authors’ experience as pharmacists. In addition, the 
study took place under conditions in which many 
of the clinicians involved did not fully support the 
research. Furthermore, no control group was included 
to compare DRP prevalence between cases with and 
those without pharmacist intervention. As a result, 
it was difficult to ascertain whether the intervention 
was the sole cause of the observed reduction in DRPs 
and clinical problems. Additionally, treatment cost-
related DRPs could not be accurately evaluated in 
the study, as all treatments were covered by the patients’ 
national health insurance.
Conclusion
This prospective study found that DRPs and clinical 
problems among CHD inpatients with at least one 
previous DRP were significantly reduced following a 
clinical pharmacist intervention. In most cases, DRPs 
were moderately severe; furthermore, the conse-
quences of not intervening in the majority of DRPs 
was projected to be moderate, potentially risking the 
health of the inpatients. These findings indicate that 
a pharmacist intervention can optimise therapy and 
improve the clinical conditions of CHD inpatients.
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